163 related articles for article (PubMed ID: 11911280)
1. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice.
Schaffrath B; Mengs U; Schwarz T; Hilgers RD; Beuth J; Möckel B; Lentzen H; Gerstmayer B
Anticancer Res; 2001; 21(6A):3981-7. PubMed ID: 11911280
[TBL] [Abstract][Full Text] [Related]
2. Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models.
Braun JM; Ko HL; Schierholz JM; Beuth J
Anticancer Res; 2002; 22(6C):4187-90. PubMed ID: 12553054
[TBL] [Abstract][Full Text] [Related]
3. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems.
Beuth J; Ko HL; Gabius HJ; Pulverer G
In Vivo; 1991; 5(1):29-32. PubMed ID: 1932621
[TBL] [Abstract][Full Text] [Related]
4. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.
Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H
Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
Fuji N; Ueda Y; Fujiwara H; Toh T; Yoshimura T; Yamagishi H
Clin Cancer Res; 2000 Aug; 6(8):3380-7. PubMed ID: 10955826
[TBL] [Abstract][Full Text] [Related]
6. Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice.
Beuth J; Schierholz JM; Ko HL; Braun JM
In Vivo; 2001; 15(5):403-6. PubMed ID: 11695237
[TBL] [Abstract][Full Text] [Related]
7. Thymic humoral factor-gamma 2 augments immune cell response and exerts antitumor activity in murine model systems.
Beuth J; Schierholz JM; Mayer G; Keisari Y
Anticancer Res; 2000; 20(6B):4473-6. PubMed ID: 11205290
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of recombinant bFGF-rViscumin fusion proteins.
Schmidt A; Möckel B; Eck J; Langer M; Gauert M; Zinke H
Biochem Biophys Res Commun; 2000 Oct; 277(2):499-506. PubMed ID: 11032750
[TBL] [Abstract][Full Text] [Related]
9. Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice.
Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
In Vivo; 1994; 8(6):989-92. PubMed ID: 7772751
[TBL] [Abstract][Full Text] [Related]
10. [Immunoactive action of mistletoe lectin-1 in relation to dose].
Beuth J; Ko HL; Tunggal L; Buss G; Jeljaszewicz J; Steuer MK; Pulverer G
Arzneimittelforschung; 1994 Nov; 44(11):1255-8. PubMed ID: 7848341
[TBL] [Abstract][Full Text] [Related]
11. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides.
Müthing J; Burg M; Möckel B; Langer M; Metelmann-Strupat W; Werner A; Neumann U; Peter-Katalinic J; Eck J
Glycobiology; 2002 Aug; 12(8):485-97. PubMed ID: 12145189
[TBL] [Abstract][Full Text] [Related]
12. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1.
Beuth J; Ko HL; Tunggal L; Steuer MK; Geisel J; Jeljaszewicz J; Pulverer G
In Vivo; 1993; 7(5):407-10. PubMed ID: 8110981
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells.
Abuharbeid S; Apel J; Sander M; Fiedler B; Langer M; Zuzarte ML; Czubayko F; Aigner A
Biochem Biophys Res Commun; 2004 Aug; 321(2):403-12. PubMed ID: 15358191
[TBL] [Abstract][Full Text] [Related]
14. Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression.
Galm O; Fabry U; Efferth T; Osieka R
Cancer Lett; 2002 Dec; 187(1-2):143-51. PubMed ID: 12359362
[TBL] [Abstract][Full Text] [Related]
15. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius S; Gabius HJ
Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
[No Abstract] [Full Text] [Related]
16. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model.
Elsässer-Beile U; Ruhnau T; Freudenberg N; Wetterauer U; Mengs U
Cancer; 2001 Mar; 91(5):998-1004. PubMed ID: 11251952
[TBL] [Abstract][Full Text] [Related]
17. The preclinical and clinical activity of aviscumine: a potential anticancer drug.
Zwierzina H; Bergmann L; Fiebig H; Aamdal S; Schöffski P; Witthohn K; Lentzen H
Eur J Cancer; 2011 Jul; 47(10):1450-7. PubMed ID: 21482461
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulating efficacy of combined administration of galactoside-specific lectin standardized mistletoe extract and sodium selenite in BALB/c-mice.
Stoffel B; Krämer K; Mayer H; Beuth J
Anticancer Res; 1997; 17(3C):1893-6. PubMed ID: 9216641
[TBL] [Abstract][Full Text] [Related]
20. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].
Beuth J; Stoffel B; Ko HL; Buss G; Tunggal L; Pulverer G
Arzneimittelforschung; 1995 Apr; 45(4):505-7. PubMed ID: 7779151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
